| Home  | About ScienceAsia  | Publication charge  | Advertise with us  | Subscription for printed version  | Contact us  
Editorial Board
Journal Policy
Instructions for Authors
Online submission
Author Login
Reviewer Login
Volume 51 Number 2
Volume 51 Number 1
Volume 50S Number 1
Volume 50 Number 6
Volume 50 Number 5
Volume 50 Number 4
Earlier issues
Volume 49 Number 3


Research articles

ScienceAsia 51 (2023): 1-8 |doi: 10.2306/scienceasia1513-1874.2023.020


In vitro antibacterial activity of panduratin A and its derivatives against vancomycin-resistant Entercoccus faecium clinical isolates


Kasarnchon Mek-yonga, Kodchaporn Jiangjamjitb, Chanita Napaswada, Anchalee Homkaewc, Napason Chabangd, Tienthong Thongpanchangb, Padungsri Dubbsa, Sunhapas Soodvilaie,*

 
ABSTRACT:     Discovery and development of antibiotics against vancomycin-resistant E. faecium (VREfm) is of high priority. The aim of this study was to investigate the therapeutic potential of panduratin A, a bioactive compound isolated from Boesenbergia rotunda, due to its antibacterial activity against Thai clinical isolates of VREfm. Susceptibility testing of panduratin A using a microbroth dilution method revealed a minimum inhibitory concentration (MIC) of 2 ?g/ml against all 39 VREfm isolates tested. The antibacterial effect of panduratin A was bacteriostatic in most isolates. The time-kill data revealed that panduratin A at 1?MIC inhibited bacterial growth for at least 24 h. The inhibitory effect was more pronounced compared with 1?MIC linezolid, a standard antibiotic for VREfm treatment. All VREfm isolates from this study exhibited vanA-type resistance supporting a crucial role of this type of vancomycin resistance in Thailand. Additionally, the antibacterial activity of the modified chemical structure of panduratin A reveals that a modification of the hydroxyl group(s) of panduratin A structure by either mono- or bis-alkylation abolished the antibacterial activity against VREfm. The present study reveals a potential use for panduratin A in the treatment of, at the least, vanA positive VREfm infection.

Download PDF

Downloads Views


a Department of Microbiology, Faculty of Science, Mahidol University, Bangkok 10400 Thailand
b Department of Chemistry, Faculty of Science, Mahidol University, Bangkok 10400 Thailand
c Microbiological Unit, Central Laboratory and Blood Bank, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok 10300 Thailand
d School of Bioinnovation and Bio-Based Product Intelligence, Faculty of Science, Mahidol University, Bangkok 10400 Thailand
e Department of Physiology, Faculty of Science, Mahidol University, Bangkok 10400 Thailand

* Corresponding author, E-mail: Sunhapas.soo@mahidol.ac.th

Received 9 Apr 2024, Accepted 10 Aug 2024